RPG Active Pharma Acquires Raghava Life Sciences API Business For Up To ₹135 Crore

Market snapshot: RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, has approved a cash-based Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and intermediates business of Raghava Life Sciences Private Limited. The transaction is valued at up to ₹135 crore on a slump-sale basis, helping the company rapidly expand its manufacturing capacity and diversify its drug ingredient portfolio.

Data Snapshot

• The transaction involves a cash consideration of up to ₹135 crore.
• The target business generated unaudited revenues of approximately ₹19 crore in FY26.
• The deal adds an EU-GMP and WHO-GMP approved plant with approximately 300 KL of installed capacity.

What's Changed

• This acquisition represents the second strategic transaction for the newly created subsidiary RPG Active Pharma, following its recent purchase of Actis Generics for ₹80 crore.
• In July 2026, RPG Life Sciences restructured by carving out its own API business (which generated ₹95.06 crore in FY26) into RPG Active Pharma, bringing in healthcare private equity investor InvAscent, which is investing ₹243.33 crore for a 40% stake.

Key Takeaways

• Adds immediate manufacturing capacity with an EU-GMP and WHO-GMP approved plant in Visakhapatnam, offering 300 KL of capacity.
• Integrates 22 commercialized APIs and 7 development-stage chemical assets into its portfolio.
• Aligns with RPG Life Sciences' goal to turn its API business into a strong third growth engine alongside domestic and international formulations.
• Funded through RPG Active Pharma's cash pool, avoiding any equity dilution for RPG Life Sciences' retail shareholders.

SAHI Perspective

RPG Life Sciences is aggressively executing its API expansion roadmap. By establishing RPG Active Pharma as a separate vehicle with a ₹700 crore phased investment plan alongside PE partner InvAscent, the company is building a highly scalable synthetic API platform. Acquiring Raghava's asset portfolio for up to ₹135 crore adds a robust pipeline of 29 molecules. While Raghava's current revenue of ~₹19 crore makes this deal look expensive at first glance (over 7x price-to-sales), the primary value lies in acquiring a high-standard, ready-to-run 300 KL EU-GMP facility, which would otherwise require substantial capital and years to build.

Market Implications

The transaction signals strong intent to capture global supply-chain shifts. It expands RPG's manufacturing base beyond Navi Mumbai to Visakhapatnam (a major pharma hub), providing geographical diversification. The market is likely to view this as a long-term positive for growth, although there could be short-term margin pressure during the integration phase.

Trading Signals

Market Bias: Bullish

The acquisition substantially enhances RPG's manufacturing capabilities and drug portfolio without equity dilution. Supported by private equity partner InvAscent's capital commitment, RPG Active Pharma has strong financial backing.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Successful integration of Raghava's facility within 30 days.
• Commercialization of the 7 pipeline molecules.
• Execution of the broader ₹700 crore capex plan.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian pharmaceutical sector has seen significant interest in API manufacturing as companies look to de-risk supply chains and move toward integrated API-to-formulation models. Building EU-GMP compliant plants from scratch is both time-consuming and regulatory-heavy; buyouts like Raghava Life Sciences and Actis Generics provide immediate market-ready capacity.

Key Risks to Watch

• Delays in combining operations or upgrading the newly acquired plant.
• Maintaining WHO-GMP and EU-GMP compliance across all newly integrated manufacturing sites.
• Paying a steep multiple on Raghava's current revenues (₹135 crore deal value vs ~₹19 crore FY26 revenue) places a heavy burden on quick scaling.

Recent Developments

In July 2026, RPG Life Sciences announced hiving off its API business into RPG Active Pharma Limited, with InvAscent committing up to ₹243.33 crore for a 40% stake. The business transfer was completed effective August 15, 2026. In addition, RPG Life Sciences approved a further investment of up to ₹65 crore in RPG Active Pharma through subscription to 21.89 lakh equity shares under a rights issue.

Closing Insight

RPG Life Sciences is rapidly transforming from a domestic-formulation-heavy player into a well-capitalized, integrated API and generic manufacturing powerhouse. While integrating multiple buyouts simultaneously (Actis and Raghava) carries execution risks, the company's clear strategic focus and strong balance sheet make it a compelling mid-cap pharmaceutical story to monitor.

High Performance Trading with SAHI.